– UK, Oxford – Oxford Biomedica plc (LON: OXB), a quality and innovation-led viral vector CDMO, today announced the appointment of Leone Patterson to its Board as an Independent Non-Executive Director, effective on 1st May 2023.
“The appointment of Leone comes at an important juncture for Oxford Biomedica, as we advance our global leadership in viral vector development and supply, providing innovative solutions to our international biopharma customers. Leone’s deep understanding of corporate finance, her experience of the US public markets and M&A, in addition to her extensive experience in the cell and gene therapy industry, will be invaluable in supporting our international strategy and further strengthening our market position,” said Board Chair, Dr. Roch Doliveux.
About Leone Patterson
Leone Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations, and governance.
She is currently CFBO at Tenaya Therapeutics (NASDAQ: TNYA), a clinical-stage company with a mission to discover, develop, and deliver potentially curative therapies, including gene therapy, for heart disease. Ms. Patterson also serves on the Board of Directors for Nkarta (NASDAQ: NKTX), a clinical-stage cell therapy company. Previously, Ms. Patterson held leadership roles, including CEO and CFO, at Adverum Biotechnologies, a gene therapy company focused on rare and ocular diseases. She has also held the role of CFO at public companies, including diagnostics firm Diadexus and specialty pharmaceuticals provider Transcept Pharmaceuticals, and earlier in her career, worked within Novartis, Chiron, and KPMG.
Leone Patterson holds a B.S. in business administration and accounting from Chapman University, an executive M.B.A. from St. Mary’s College, and is a Certified Public Accountant (inactive).
M.s Leone Patterson said: “I am honored to join the Board of Oxford Biomedica, a global innovation-led CDMO dedicated to enabling the development of life-saving cell and gene therapies. I look forward to working with the Board and contributing my expertise to help advance the Company’s strategy.”
About Oxford Biomedica
Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life-changing therapies to patients worldwide.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind most gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus, and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialization. These capabilities are supported by robust quality assurance systems, analytical methods, and depth of regulatory expertise.
Oxford Biomedica, an FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, and a US-based subsidiary, Oxford Biomedica Solutions, based near Boston, MA, US.
Source: https://www.oxfordbiomedica.co.uk/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
